Last SFr.89.60 CHF
Change Today 0.00 / 0.00%
Volume 0.0
As of 11:45 AM 08/21/14 All times are local (Market data is delayed by at least 15 minutes).

zimmer holdings inc (ZMH) Snapshot

Open
SFr.89.60
Previous Close
SFr.89.60
Day High
--
Day Low
--
52 Week High
07/14/14 - SFr.95.90
52 Week Low
08/28/13 - SFr.71.05
Market Cap
15.1B
Average Volume 10 Days
232.2
EPS TTM
--
Shares Outstanding
168.9M
EX-Date
06/25/14
P/E TM
--
Dividend
SFr.0.86
Dividend Yield
0.82%
Current Stock Chart for ZIMMER HOLDINGS INC (ZMH)

zimmer holdings inc (ZMH) Related Businessweek News

No Related Businessweek News Found

zimmer holdings inc (ZMH) Details

Zimmer Holdings, Inc., through its subsidiaries, designs, develops, manufactures, and markets orthopedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. The company offers orthopedic reconstructive devices that restore function lost due to disease or trauma in joints such as knees, hips, shoulders, and elbows; dental reconstructive implants, which restore function and aesthetics in patients who have lost teeth due to trauma or disease; spinal devices that are utilized by orthopedic surgeons and neurosurgeons in the treatment of degenerative diseases, deformities, and trauma in various regions of the spine; and trauma devices used primarily to reattach or stabilize damaged bone and tissue to support the body’s natural healing process. It also provides related surgical products comprising surgical supplies and instruments designed to aid in orthopedic surgical procedures and post-operation rehabilitation; and other healthcare related services. The company’s principal customers include orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, and healthcare dealers, as well as agents, healthcare purchasing organizations, or buying groups. Zimmer Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.

Founded in 1927

zimmer holdings inc (ZMH) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $904.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $525.7K
President of Europe, Middle East and Africa
Total Annual Compensation: $579.0K
President of Asia Pacific
Total Annual Compensation: $537.9K
Compensation as of Fiscal Year 2013.

zimmer holdings inc (ZMH) Key Developments

Nobel Biocare Said To Draw Interests

Nobel Biocare Holding AG (SWX:NOBN) ) that’s exploring a sale, has attracted interest from potential buyers including EQT Partners AB and Danaher Corp. (NYSE:DHR), said people with knowledge of the matter. Nobel Biocare was initially approached by EQT with an offer of about CHF 17 a share, which would have valued the company at about CHF 2.1 billion said the people, who asked not to be identified because talks are private. The offer prompted Nobel Biocare and its adviser Goldman Sachs Group Inc. (GS) to invite other bids as it seeks a higher price, the people said. Other companies such as DENTSPLY International Inc. (NasdaqGS:XRAY) and buyout firms are also expected to look at Nobel Biocare, the people said. Potential buyers include Straumann Holding AG (SWX:STMN), Sirona Dental Systems Inc., Johnson & Johnson (NYSE:JNJ), Medtronic, Inc. (NYSE:MDT), Zimmer Holdings, Inc. (NYSE:ZMH), Henry Schein, Inc. (NasdaqGS:HSIC), and 3M Company (NYSE:MMM), according to a note on July 30 from Lisa Bedell Clive, a London-based analyst at Sanford C. Bernstein & Co. Nobel Biocare could sell for as much as CHF 18 a share, she said in the note.

Zimmer Holdings, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revises Earnings Guidance for the Year Ending December 31, 2014; Provides Earnings Guidance for the Third Quarter of 2014

Zimmer Holdings, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported net sales of $1,182.9 million against $1,169.5 million a year ago. Operating profit was $259.3 million against $210.4 million a year ago. Earnings before income taxes were $236.4 million against $196.0 million a year ago. Net earnings of the company were $176.5 million against $152.1 million a year ago. Diluted earnings per share were $1.03 against $0.89 a year ago. Adjusted net earnings were $254.7 million against $243.4 million a year ago. Adjusted diluted earnings per share were $1.49 against $1.43 a year ago. Adjusted operating profit in the quarter amounted to $355.4 million. Operating cash flow for the quarter amounted to $254.1 million, an increase of 34% from $189.7 million in the second quarter of 2013. The increase is driven primarily by favorable accounts receivable trends in Europe, Middle East and Africa operating segments and lower tax payments relative to the same period prior year. Capital expenditures for the quarter totaled $94.6 million, including $62.6 million for instruments and $32 million for property, plant and equipment. For the six months, the company reported net sales of $2,344.4 million against $2,308.4 million a year ago. Operating profit was $557.7 million against $508.6 million a year ago. Earnings before income taxes were $522.3 million against $479.7 million a year ago. Net earnings of the company were $398.0 million against $370.7 million a year ago. Diluted earnings per share were $2.32 against $2.17 a year ago. Net cash provided by operating activities was $442.9 million against $370.2 million a year ago. Additions to instruments were $112.0 million against $116.3 million a year ago. Additions to other property, plant and equipment was $63.4 million against $40.3 million a year ago. Adjusted net earnings were $512.8 million against $484.2 million a year ago. Adjusted diluted earnings per share were $2.99 against $2.84 a year ago. For the third quarter, the company expects revenues to increase between 2% and 2.5% constant currency and between 2.5% and 3% on a reported basis when compared to the prior year. Adjusted diluted earnings per share expected to be in the range of $1.29 to $1.31. For the year ending December 31, 2014, the company expects diluted earnings per share to be $4.65 to $4.75. Adjusted diluted earnings per share are expected to be $6.00 to $6.10. Prior guidance for full-year 2014 reported and adjusted diluted earnings per share was $4.90 to $5.10 and $6.00 to $6.20, respectively. This updated guidance reflects estimated charges for inventory and manufacturing related expenses, quality and operational excellence initiatives, certain claims and special items of $250 million on a pre-tax basis, and an additional $70 million for expenses related to the pending Biomet merger, totaling $320 million or approximately $1.35 per diluted share, on an after-tax basis. The estimated full year tax rate remains at 25.5%. On a reported basis, revenues are projected to be between 1.5% and 2.5% above 2013 results.

Zimmer Holdings, Inc., Q2 2014 Earnings Call, Jul 24, 2014

Zimmer Holdings, Inc., Q2 2014 Earnings Call, Jul 24, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ZMH:SW SFr.89.60 CHF 0.00

ZMH Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ZMH.
View Industry Companies
 

Industry Analysis

ZMH

Industry Average

Valuation ZMH Industry Range
No financial data is available for ZMH.
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ZIMMER HOLDINGS INC, please visit www.zimmer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.